Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: primary results of the ARCHER study - PubMed
a day ago
- #Cannabidiol
- #Cardiac Recovery
- #Myocarditis
- The ARCHER study investigated the effects of pharmaceutically produced cannabidiol (CBD) on myocardial recovery in patients with acute myocarditis.
- This was a double-blind, placebo-controlled phase 2 study involving 109 patients randomly assigned to CBD or placebo for 12 weeks.
- Primary endpoints included changes in extracellular volume (ECV) and global longitudinal strain (GLS) measured via cardiac magnetic resonance (CMR).
- Results showed no statistically significant change in ECV or GLS, though a trend toward reduced ECV was observed.
- Left ventricular (LV) mass was significantly reduced in the CBD group compared to placebo.
- CBD was found to be safe and well-tolerated, with no loss to follow-up.
- Further research is needed to explore CBD's therapeutic potential in inflammatory cardiac conditions.